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Summary
When deep X-ray therapy became available it soon was used in the treatment of
supratentorial gliomas. Presumably because surgely alone was a disappointing
venture in high grade gliomas as the glioma rapidly recurred even after major
resections and because of the general notion of the effectivity of X-ray therapy in
the treatment of cancer. At the end of the 1970s and the beginning of the 1980s a
number of important advances took place lvhich form the basis of modern
radiotherapy for gliomas. In the first place the technological improvement in the
tools of radiotherapy as the introduction of computer technology with CT
scanning, high energy radiation, computerized treatment planning which allowed
for accurate and reproducible treatment. Secondly, randonrized trials proved tlre
value of radiotherapy in GBM by prolonging survival. In the third place the
introduction of histopathological classification systems such as the WHO system
resulted in the identification of groups of gliomas with different genesis and
prognosis in which the role of radiotherapy was different.
It was with basically these tools and knowledge that supratentorial gliomas were
treated since the end of the 1970s up until the present day. In this thesis the
impact on radiotherapy of several new developments in diagnostic and
therapeutic possibilities were studied.
In chapter I a large patient series (n:839) with a supratentorial glioma treated in
Groningen in the period 1979 until 1999 is analysed in relation to radiotherapy.
The primary feature of the analysis is the histopathologic grading and
classification. It provides the most imporlant prognostic factor for survival and it
determines the indication and outcome of radiotherapy. However other
prognostic factors also influence treatment decisions regarding radiotherapy such
as age and performance of the patient . To some extent these prognostic factors
are related to each other. In general low grade gliomas occur in younger patients
and the high grade gliomas in older patients. 'fherefore after histopathologic
grading age has lost some of its prognostic value. In the literature of the glioma
the role of radiotherapy is separately analysed for each histopathologic category.
Therefore the same approach was follorved in this analysis.
In GBM the place of radiotherapy is best documented. It doubles the MST with
an optimum dose of 60 Gy in 6 weeks local field inadiation and is the standard
therapy after surgery. However radiotherapy in GBM is selectively applied in
patients with the best performance. In Groningen radiotherapy was applied in the
majority of GBM patients excluding those with poor performance. Recently
selection factors were used involving the introduction of short fractionation
schemes e.g. l5 x 3 Gy with the reduction of overall treatment time of 3 weeks
for patients with less favourable prognostic factors such as age > 50 years and
Karnovsky performance < 70.
Presently in A there is no evidence that radiotherapy prolongs survival.
Therefore in prognostically favourable patients with young age and good
perfonlance radiotherapy is withheld. ln symptomatic pal ients or in recurent
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gliomas radiotherapy is applied also as a consequence of lack of therapeutic
alternatives besides surgery and the evidence that A may respond to radiotherapy.
In Groningen radiotherapy was widely applied in A although the timing of
radiotherapy was not evaluated (immediately after first surgery or after
recurrence).
Technological improvements in radiotherapy did not improve survival in glioma.
This probably means that technically more precise radiotherapy does not affect
local control in glioma as long as the biological effectiveness of radiotherapy is
unchanged. However radiotherapy dose reduction to normal brain tissue likely
has reduced radiation induced brain damage which is of benefit to patients with a
longer survival.
The problem in grading the astrocytic tumours is reflected in the definition of the
AA and consequently also the role of radiotherapy. AA are treated as GBM
although no separate data on the effectiveness of radiotherapy in AA exists.
Histopathologically the AA cannot be sharply demarcated from A. This implies
that some long term surviving AA patients are incorrectly graded A. In these
patients the application of high dose (60 Gy) irradiation after surgery is of no
proven value. The appearance of an oligodendroglial component in a glioma
whether in case of a pure O or as a component in an A implies a better prognosis
in comparison with the pure astrocytic tumours of corresponding grade of
malignancy. Because these tumours are less frequent than A, the O tend to be
included in low grade glioma sflrdies and AO in high grade glioma studies.
Therefore evidence regarding the role ofradiotherapy in O is lacking. In general
the same treatment approach is followed in O as in the astrocytic tumours of
corresponding grade of malignancy. As O are biologically different from A with
respect to chemosensitivity, genetically and possibly radiosensitivity, separate
studies of O are needed in which the role of radiotheraov is defined.
Further refinements of the classification and grading system came from tumour
kinetic studies. Tumour growth rate depends on the balance of cell proliferation
and cell death. The proliferation rate was studied by MIB-1 which is an antibody
against Ki-67 expressing non-G0 cells. This MIB-l labelling was possible on
archival paraffin embedded material allowing for large retrospective studies. The
rate of cell death or apoptosis can also be measured on archival material using
TUNEL labelling, In chapter 2 both MIB-l labelling index and TLNEL labelling
index were used in a large retrospective patient series to assess their prognostic
value. These indices were used within the current WHO classification system and
not as a substitute for classification and grading. Proliferation and apoptosis were
assessed within each histopathological category. It was found that the apoptotic
rate appeared to be associated with the proliferation rate and was not an
independent prognostic marker. For radiotherapy purposes the relevant
distinction between A and AA is improved by using MIB-I. However from a
biological point of view the distinction between A and AA is somewhat artificial
as gliomas are regionally heterogeneous implying that the piece of tissue studied
might not be representative for the tumour as a whole and in the course of time
the low grade glioma has a tendency to progress to higher grades of malignancy.
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Another aspect concerns the oligodendroglial tumours with a higher proliferation
rate compared to the astrocytic tumours although they had a better prognosis.
This apparent discrepancy was already known in the concept that the number of
mitosis was of minor prognostic value in O. This points again to a different
biology of oligodendroglial tumours and increases the uncertainty regarding the
role of radiotherapy.
With immunohistochemical analysis of protein products the activity of genes
involved in the regulation of proliferation and apoptosis can be investigated. In
chapter 3 some of these proteins are studied in relation to the outcome of
radiotherapy. Some patients with a low grade glioma experience a long term
recurrence free survival (ttO years) and it was shown that the gliomas in these
cases had a low MIB-LI with low p53 protein expression possibly indicating non-
mutated IP5-1. TP53 plays a central role in regulating cell proliferation ,
differentiation , DNA repair and apoptosis. Mutations in TP 53 are strongly
associated with progression of A to high grade astrocytomas. It is possible that in
A low p53 immunoreactivity is associated with non-mutated TP 53 and is
accompanied by a low tendency to increase proliferation and progression rates.
This is reflected by the low MIB LI and the long term progression free survival
found in these tumours. These results further suggest that deregulation of
proliferation is the hallmark of glioma progression. The protein expression of the
genes involved in the apoptotic process did not differ between recurrent and non-
recurring A. This suggests that the regulation of these apoptotic processes is not
primarily involved in glioma progression.
In oligodendroglial tumours it is expected that O with detectable p53
immunoreactivity progress more rapidly to a higher grade of malignancy.
However, mutations in TP 53 are less frequent than in A. The analysis of pairs of
primary and recurrent low grade gliomas showed an increase in proliferation
parameters in the recurrent tumour compared to its primary. This is in accordance
with the progression in malignancy of low grade gliomas. However this study
suggest that radiotherapy plays no role in this process It may be hypothesized
that some low grade gliomas are programmed to long term survival with or
without radiotherapy and radiotherapy if applied does not increase proliferation
and apoptosis in the recurrent tumour.
Radiotherapy does not "cure" glioma but radiotherapy certainly delays tumour
progression by reducing tumour size and prolonging survival in GBM. To
achieve this goal radiotherapy has to be directed to the central tumour mass only,
without the need to encompass all areas of tumour cell invasion. New imaging
modalities have been introduced. MRI with its superior soft tissue contrast and 3-
dimensional depiction resulted in improved imaging of the glioma. The
consequence of MRI for radiotherapy treatment planning was investigated in
chapter 4. If the glioma showed no contrast enhancement e.g. in case of a low
grade glioma, the observers had to rely on minor changes in density when using
CT. This leads to greater interobserver variation than when in the use of MRI T2
weighted images for radiotherapy treatment field design. As the MRI T2 high
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signal area encompasses the fumour area and because from within this region the
low grade glioma will progress it follows that in case of a non-contrast enhancing
glioma MRI should be used lbr radiotherapy treatment planrring.
Other new imaging modalities include PET and MRSI. In chapter 5 the IH
spectroscopic imaging is introduced featuring some metabolic characteristics of
the glioma. In the central tumour mass the NAA (parameter of functional
neurones) is depressed consistent with neuronal loss and replaced by an increase
of choline. Choline reflects the increased phosphocholine turnover in relation to
membrane biosynthesis of proliferating cells. Lactate was also found in some
gliomas reflecting increased glycolysis which is a feature of the metabolism of
malignant cells. Horvever, with the spectroscopic technique used, the lactate
peaks cannot be fully discriminated from free fatty acids.
In chapter 6 tyrosine PET is validated as a method to visualize and quantify
protein synthesis of the glioma. Regardless of the malignancy grade the glioma
exhibits an increased protein synthesis which can be measured with tyrosine
PET. tn some cases the area of increased choline depicted with MRSI seemed to
conelate with the area of increased PSR both indicatins the location of vital
tumour tissue.
After radiotherapy the glioma will progress from within 2.5 cm of the outer rim
of the contrast enhancing region in case of a GBM and from within the MRI T2
region in case of a low grade glioma. Therefore using MRI and CT is adequate
for the purpose of treatment field design whereas metabolic imaging either with
PET or MRSI is of no practical consequence for this purpose. On the other hand,
PET and MRSI can be used for monitoring the radiotherapy treatment response
as CT and MRI cannot discriminate vital tumour from necrotic tumour tissue,
radiation induced brain damage or effects of surgery. In chapter 7 proton
spectroscopic imaging (MRSI) was used to monitor the response on radiotherapy
of brain gliomas. To be certain that a true response of tumour metabolism was
measured only biopsied gliomas were investigated. Metabolic responses found in
several gliomas were the decrease of choline and lactate was accompanied by a
shrinkage of tumour diameter on MRI. In case of low grade gliomas this adds to
the evidence that although radiotherapy has no clear effect on survival it may
induce tumour regression and tumour devitalization. The solid tumour mass of
the glioma irreversibly has destroyed the existing brain parenchyma which is
indicated by the irreversibly decreased NAA.
With longer follow-up studies supported by histopathological verification the
value of metabolic imaging could be further improved although in the case of a
brain tumour the taking of multiple biopsies in time is a difficult aim to tealize.
However, comparison of proton spectroscopy with histopathology has been
r41
performed in other studies in the case of differentiating radionecrosis from
recurrent brain glioma. Proton spectroscopy proved a useful tool for this purpose.
In chapter 8 the response to radiotherapy in glioma was monitored with the use
of tyrosine PET. The advantage of using tyrosine is the capacity to calculate the
true PSR of the glioma before and after radiotherapy. The main results were
again the response on radiotherapy of the volume of increased tyrosine uptake
with no decrease of the PSR in the remaining tumour. This probably means that
radiotherapy does not completely devitalize the glioma although it can induce
tumour regression.
Conclusiorts
In this thesis the radiotherapy of patients with brain gliomas is studied from a
clinical point of view. Historically, radiotherapy was used as a treatment
modality for these incurable tumours even before the evidence came out of the
survival benefit for GBM patients with radiotherapy and before the introduction
of "computerized radiotherapy" with treatment planning, CT imaging and high
energy inadiation. Using these modern techniques two decades of radiotherapy
for glioma in Groningen were studied establishing the well known prognostic
factors for survival with histopathologic classification and grading as the most
important. Therefore the role of radiotherapy had to be studied for each
histopathological category. Radiotherapy definitely improves survival in GBM
although for the other histopathological categories the survival benefit is not
proved. The lack of a curatjve opportunity with radiotherapy leads to the clinical
policy of withholding radiotherapy in patients with a poor performance and in
low grade glioma patients with prognostically favourable factors to avoid
radiation-induced brain damage. The use of a grading system in astrocytic
tumours implies an uncertainty in the discrin,ination between A and AA which
has its consequence for the indication of radiotherapy. In this field the main
advantage of the use of proliferation markers e.g. the MIB-LI has been
demonstrated.
This study emphasizes the importance of the proiiferation rate and not the
apoptotic rate for the discrimination between high and low grade gliomas and the
identification of long term recurrence free gliomas. The p53 protein has a role in
the control of proliferation and apoptosis. This study suggests that long term
prognosis in glioma depends on a norynal functioning of TP53 implying a
controlled low proliferation rate. Apoptosis does not seem to play a role.
Furthermore this study suggests that radiotherapy does not influence changes in
proliferation or apoptosis in recurrent low grade gliomas. New imaging
modalities changed the practice of radiotherapy but do not affect prognosis. MRI
is to be preferred in the target definition of low grade gliomas. Metabolic imaging
with MRSI or tyrosine PET can be used to monitor radiotherapy response of the




Molecular biology and genetics will provide new prognostic factors, refinement
of the classification and grading system and predictive testing for planning of
treatment strategies. Some examples are the prognostic value of MIB-1 and p53
as outiined in this thesis. Another example is the chromosomal aberration in lp
and 19q predicting the response to chemotherapy in O.
New conformal radiotherapy techniques with intensity modulated radiotherapy
(IMRT), stereotactic conformal radiotherapy (SCRT) or proton therapy may be
used in reduction of radiotherapy dose to certain eloquent brain areas possibly
leading to a decrease in radiation induced brain damage. An example is the
avoidance of the brain areas containing proliferating and apoptosis sensitive stem
cells e.g. the forebrain subependyma nd the dentate gyrus of hippocampus.
New neuronavigation techniques in neurosurgery correlate the position of
neurosurgicai equipment during operation to its corresponding site on brain
images. This will allow a correlation between the site of tumour sampling on
imaging with histopathology. This implies an integration of imaging and
pathology reducing the problem of tumour heterogeneity. If this will be extended
to correlate metabolic imaging with histopathology new avenues will be opened
in efforts to escalate the radiotherapy dose to areas of persistent vital tumour
tissue. If these areas are smali enough no symptomatic radionecrosis is to be
expected obviating the need of repeated surgery. The idea of dose escalation
with IMRT, SCRT, proton therapy or radiosurgery is based on the concept of a
spatial discrimination between the tumour and normal tissue. Although this
approach will not cure the glioma because of the clonogenicity of the tumour
cells widely invading into functional brain parenchyma. However, a meaningful
increase in survival may be expected. To cure the glioma the therapy inevitably
has to be directed to these migrating tumour cells. Recently this was attempted by
using neural stem cells. In a mouse model neural stem cells were engineered to
produce the therapeutic immunomodulator interleukin-4. After injection into
brain these therapeutic cells may travel along the white matter and potentially
target the brain invading neoplastic cells (Benetletti 5.,Pirola 8., Pollo 8., Mttgrassi L.,
Crazia M., Rigamonti D. Cene therapy of etperimental brain tumors using neural progenitor cells.
Nature Med. vol 6 aprit 2000 . 447-450). Perhaps some of these techniques can be further
developed to sensitize the invading tumour cells to low dose radiotherapy.
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